Arcus Biosciences, Inc. (NYSE:RCUS – Get Free Report)’s share price hit a new 52-week low on Thursday. The company traded as low as $15.69 and last traded at $15.96, with a volume of 55,190 shares changing hands. The stock had previously closed at $15.76.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on RCUS. Wedbush lowered their price target on Arcus Biosciences from $49.00 to $45.00 and set an “outperform” rating for the company in a research report on Thursday, November 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Arcus Biosciences in a report on Friday, September 11th. Wall Street Zen lowered Arcus Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. Leerink Partners lifted their price objective on Arcus Biosciences from $46.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $42.00 target price on shares of Arcus Biosciences in a report on Friday, August 7th. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Arcus Biosciences presently has an average rating of “Moderate Buy” and a consensus target price of $39.36.
View Our Latest Analysis on RCUS
Arcus Biosciences Stock Up 1.2%
The firm’s 50-day moving average price is $21.85 and its 200-day moving average price is $24.36. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.34 and a quick ratio of 3.34. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -4.36 and a beta of 1.04.
Arcus Biosciences (NYSE:RCUS – Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.11). Arcus Biosciences had a negative net margin of 453.00% and a negative return on equity of 91.65%. The business had revenue of $9.00 million for the quarter, compared to analyst estimates of $7.58 million. During the same quarter in the previous year, the firm posted ($1.27) EPS. The business’s revenue was down 65.4% compared to the same quarter last year. Sell-side analysts forecast that Arcus Biosciences, Inc. will post -3.49 earnings per share for the current fiscal year.
Insider Transactions at Arcus Biosciences
In other Arcus Biosciences news, CAO Alexander Azoy sold 2,827 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $30.00, for a total value of $84,810.00. Following the transaction, the chief accounting officer directly owned 39,581 shares of the company’s stock, valued at $1,187,430. This trade represents a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 7.60% of the company’s stock.
Institutional Investors Weigh In On Arcus Biosciences
Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Arcus Biosciences in the second quarter valued at approximately $506,113,000. Parkman Healthcare Partners LLC purchased a new stake in shares of Arcus Biosciences during the second quarter valued at approximately $28,341,000. Bank of America Corp DE purchased a new stake in shares of Arcus Biosciences during the second quarter valued at approximately $25,759,000. Bank of New York Mellon Corp purchased a new stake in shares of Arcus Biosciences during the second quarter valued at approximately $16,741,000. Finally, Aberdeen Group plc lifted its position in shares of Arcus Biosciences by 62.4% during the third quarter. Aberdeen Group plc now owns 1,056,679 shares of the company’s stock worth $27,294,000 after purchasing an additional 405,967 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.
Arcus Biosciences Company Profile
Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2015 and headquartered in Hayward, California, the company researches therapies that target immune pathways and other processes involved in tumor growth. Its pipeline consists of investigational medicines, including antibody and small-molecule candidates designed to be used alone or in combination. Arcus’s research has focused on areas such as checkpoint inhibition and the adenosine pathway; its candidates are under clinical development and are not established treatments.
Featured Articles
- Five stocks we like better than Arcus Biosciences
- The Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027
- Lowe’s Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the Math
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
- Apple’s Next Margin Defense Could Be Hiding in Your Wallet
Receive News & Ratings for Arcus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
